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Abstract
Background: Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) is an
autosomal recessive disorder of renal calcium and magnesium wasting frequently complicated by
progressive chronic renal failure in childhood or adolescence.
Methods: A 7 year old boy was investigated following the findings of marked renal insufficiency
and nephrocalcinosis in his 18-month old sister. He too was found to have extensive
nephrocalcinosis with increased fractional excretion of magnesium: 12.4% (<4%) and
hypercalciuria: 5.7 mmol (< 2.5/24 hours). He had renal impairment, partial distal renal tubular
acidosis and defective urinary concentrating ability. Therapy with thiazide diuretics and magnesium
supplements failed to halt the progression of the disorder. Both children subsequently underwent
renal transplantation. Both children's parents are unaffected and there is one unaffected sibling.
Results: Mutation analysis revealed 2 heterozygous mutations in the claudin 16 gene (CLDN16) in
both affected siblings; one missense mutation in exon 4: C646T which results in an amino acid
change Arg216Cys in the second extracellular loop of CLDN16 and loss of function of the protein
and a donor splice site mutation which changes intron 4 consensus splice site from 'GT' to 'TT'
resulting in decreased splice efficiency and the formation of a truncated protein with loss of 64
amino acids in the second extracellular loop.
Conclusion: The mutations in CLDN16 in this kindred affect the second extra-cellular loop of
claudin 16. The clinical course and molecular findings suggest complete loss of function of the
protein in the 2 affected cases and highlight the case for molecular diagnosis in individuals with
FHHNC.
Background
Hereditary renal tubular disorders associated with
impaired renal conservation of salt, calcium and magne-
sium comprise a wide range of clinical symptoms, meta-
bolic/biochemical abnormalities and underlying genetic
defects. Mutations in several genes involved in renal elec-
trolyte transport have been identified as the cause of many
of the tubular disorders such as Bartter's syndrome, Gitel-
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man syndrome, isolated renal magnesium loss or familial
hypomagnesaemia with hypercalciuria and nephrocalci-
nosis (FHHNC) [1-6].
FHHNC is an autosomal recessive disorder of renal cal-
cium and magnesium wasting often complicated by, as
yet, unexplained progressive chronic renal failure during
childhood or adolescence. Patients usually present with
recurrent urinary tract infections, polyuria/polydipsia,
nephrolithiasis/calcinosis. Loss of function mutation of
the claudin 16 (CLDN16) gene have been identified as the
underlying genetic defect in the majority of patients
affected with FHHNC. CLDN16  encodes claudin 16, a
tight junction protein which is expressed in the thick
ascending limb (TAL) of the loop of Henle [5].
We report 2 heterozygous mutations of this gene in 2 sib-
lings with this disorder and provide information about
their phenotypic presentation and clinical course. We also




The index case, 2 siblings and his parents underwent clin-
ical, biochemical and genetic analyses. The index case is
the oldest sibling and aged 7 at the time of hospital admis-
sion for diagnostic work-up as his younger sister had been
diagnosed with nephrocalcinosis and hypomagnesaemia,
aged 18 months. She was first thought to have renal prob-
lems at the age of 18 months, having been investigated for
failure to thrive from the age of 10 months. She had recur-
rent urinary tract infections and was shown to have reflux
into one ureter and impaired renal function. She did not
have hypertension at the time of presentation and did not
require anti-hypertensive treatment until later when she
was started on Atenolol 25 mg/daily. Her blood pressure
was subsequently well controlled on this treatment.
Unlike his younger sister, the index case had not had any
acute presentations necessitating hospital admissions ear-
lier. He had been generally well but closer questioning
revealed a history of polyuria/polydipsia, unexplained
feverish illnesses, possibly due to frequent urinary tract
infections since early childhood. In contrast to his
younger sibling, he had marked hypertension. Physical
examination revealed arterial hypertension (B.P 170/130
mmHg). His height was 126.6 cm (75th centile) and his
weight 23.5 kg (50th centile). Examination of his heart,
lungs, abdomen and nervous system was unremarkable.
There was no evidence of ocular abnormalities or hearing
impairment. They are Caucasians and there was no history
of parental consanguinity.
Preliminary laboratory investigations in the index case
revealed renal impairment (sodium: 142 mmol/L, potas-
sium: 3.6 mmol/L, urea: 7.1 mmol/L, creatinine: 93
mcmol/L, GFR: 51 mls/min/1.73 m2). Serum calcium was
normal (2.38 mmol/L), magnesium was low (0.63 mmol/
L, reference range 0.7–1.0 mmol/l), phosphate was 1.52
mmol/L. Parathyroid hormone (PTH) was elevated, 600
ng/L (normal range: < 120). Urinary analyses revealed
hypercalciuria, 5.67 mmol/24 hours (normal range: <
2.5/24 hours). Fractional excretion rate of magnesium
was elevated: 12.4% (< 4%). Water deprivation test indi-
cated a defect in urinary concentrating ability. Ammo-
nium chloride loading test revealed a distal defect in
urinary acidification. Abdominal plain radiographs
revealed bilateral nephrocalcinosis and large kidneys.
Based on the clinical and laboratory findings a diagnosis
of FHHNC was made. Treatment was started with magne-
sium supplementation and chlorothiazide. The hypercal-
ciuria was resistant to chlorothiazide which was later
discontinued as it aggravated hypomagnesaemia. He was
also treated with propanolol 40 mg three times daily and
hydralazine 3.5 mg three times daily. His blood pressure
was satisfactory on these medications and came down to
100/60. The index case's growth rate was not compro-
mised to the same extent as his younger sibling. Treat-
ment, however failed to prevent the progression of renal
failure in both children. They eventually underwent renal
transplantation. The younger sibling required renal trans-
plantation at an earlier age as the decline in GFR was more
rapid in her case compared to her older sibling whose
renal functions were better preserved. Her GFR was 27
mls/min at age 5, having declined from 32 ml/min in 2
years. Her pre-transplant results at age 9 years showed
normal serum electrolytes, urea: 35.2 mmol/L, creatinine:
454 mcmol/L, calcium: 1.69 mmol/L, phosphate: 1.69
mmol/L, magnesium: 0.73 mmol/L. The affected younger
sibling received a deceased donor transplant. In contrast
the index case's GFR remained stable at 40 ml/min during
his early teenage years. However his renal function
declined further in his late teens and he received a live
donor kidney in young adulthood from his father.
All subjects, including the index case and his affected
younger sibling who are now adults aged 33 and 28 years
respectively gave their consent. The parents and the unaf-
fected sibling were also screened. The parents and unaf-
fected child's biochemical results were normal. They had
no history of renal calculi. Urinary calcium, magnesium
and phosphate excretion was normal. Blood was also
obtained from all members of the family for genetic anal-
yses after informed consent. This had been approved by
the Research Ethics Committee of Guy's Hospital, UK.
Consent for publication was obtained from the patients.
Molecular studies
DNA was extracted from peripheral blood using standard
protocols. CLDN16 mutation screening was performed byBMC Nephrology 2008, 9:12 http://www.biomedcentral.com/1471-2369/9/12
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single-strand conformation polymorphism analysis [7].
Amplified products of the coding sequence (exons 1 to 5)
were separated on a denaturing polyacrylamide gel by
electrophoresis. The exons with the conformational vari-
ants compared to controls were then sequenced directly.
Mutational analysis of the CLDN16 gene was carried out
by direct sequencing of both strands of the coding region
and the adjacent exon/intron boundaries following
polymerase chain reaction (PCR) amplification of
genomic DNA with flanking intronic primers. All primer
sequences are available upon request. DNA sequencing
was performed using the fluorimetric method (Big-Dye
Terminator Cycle sequencing kit; ABI 3700 DNA
sequencer, Applied Biosystems, Foster City, Ca, USA)
according to the manufacturer's protocol.
Results
Two types of conformational variants were identified in
exon 4 in all family members compared to controls. This
is illustrated in Figure 1. Lanes 2 and 5 represent the
affected children. Lanes 1, 3, 4 correspond to the unaf-
fected family members who are heterozygote carriers.
Direct sequencing of exon 4 revealed 2 heterozygous
mutations; one mis-sense mutation 646 C> T (inherited
from the maternal allele) and a second novel mutation
which is a splice site mutation 784 +1 G>T (inherited
from the paternal allele) as shown in Figure 2 (Genbank
Acc number NM_006580). The unaffected sibling was a
heterozygous carrier of the paternal mutation (784 +1
G>T). The missense mutation is located in the second
extracellular loop of claudin 16 and leads to an amino
acid change from Arginine to Cysteine. This missense
mutation has been shown following expression analysis
to result in complete loss of function of the protein [8].
The 784 +1 G>T splice mutation results in a change in the
intronic consensus splice site such that 'GT' is changed to
'TT'. This leads to a 224-fold decrease in splice efficiency
as calculated from the automated splice site analysis. The
mutation leads to skipping of exon 4 with a loss of 64
amino acids in the second transmembrane domain and is
likely to lead also to loss of function.
Discussion
Familial hypomagnesaemia with hypercalciuria and
nephrocalcinosis is a rare autosomal recessive renal tubu-
lar disorder that is frequently complicated by chronic
renal failure in early childhood or adolescence [5,9,10].
Both cases exhibited the most commonly observed renal
complications. They did not have any extra-renal manifes-
tations. The clinical observations and clearance studies
point to impaired reabsorption of magnesium and cal-
cium in the TAL of the loop of Henle as the primary defect.
The TAL of the loop of Henle plays a predominant role in
the renal reabsorption of divalent cations which mainly
pass via paracellular flux [11]. Treatment failed to prevent
progression of the disease in the 2 cases presented here as
previously reported for other patients [9]. The hetero-
zygous carriers had no evidence of hypercalciuria and/or
nephrolithiasis. Renal transplantation in both affected
individuals corrected the abnormal renal magnesium and
calcium handling. It is unclear why renal failure occurs in
FHHNC and has been linked to the nephrocalcinosis.
However in other renal tubular disorders where extensive
medullary nephrocalcinosis occurs such as in ante-natal
Bartter syndrome, progressive renal failure to the same
extent as that seen in FHHNC is not observed [12]. This
may be related to the different molecular defects in these
2 tubulopathies.
Genotyping of the index case and the family members
revealed 2 heterozygous mutations of CLDN16. The
CLDN16 gene codes for a protein which is almost exclu-
sively expressed in the TAL of the loop of Henle and spans
the lipid bilayer 4 times with 2 extracellular loops [13].
Over 20 different mutations have been identified to date.
The majority of mutations (67%) are single-nucleotide
changes which occur in the first extra-cellular loop [9]. We
detected 2 mutations in exon 4 which codes for the sec-
Single strand polymorphism analysis of the amplified products  of exon 4 of CLDN16 gene showing the conformational vari- ants Figure 1
Single strand polymorphism analysis of the amplified 
products of exon 4 of CLDN16 gene showing the con-
formational variants. Heterozygous carriers: Lanes 1: 
Unaffected sibling, Lane 3: Mother, Lane 4: Father. Affected 
cases: Lanes 2 and 5. Control: Lane 6. Blank: Lane 7.BMC Nephrology 2008, 9:12 http://www.biomedcentral.com/1471-2369/9/12
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ond extracellular loop. Very few mutations have been pre-
viously described in the second extracellular loop. A
recently reported mutation in exon 4 of the CLDN16 gene,
located in the 4th transmembrane domain, was shown to
be been associated with extreme short stature which was
not a clinical feature in our cases [14]. The missense muta-
tion described here leads to a change from arginine to
cysteine. In general cysteine residues are known to lead to
conformational changes or alterations in trafficking or ion
selectivity. This mutation has previously been reported in
a Japanese patient and a substitution of the same amino
acid to threonine has also been reported in an Algerian
family with FHHNC [15,9]. This may indicate a mutation
cluster at this site in the second extra-cellular loop and
confirms the physiological importance of the second
loop. Although previous mis-sense mutations have been
described in exon 4, this is the first splice site mutation
reported in this region of the CLDN16 gene. The splice site
mutation leads to a significant reduction in splice effi-
ciency and the formation of a truncated second extra-cel-
lular loop. The 2 mutations described here resulted in
classical FHHNC with severe and rapid deterioration of
renal function. This may be explained by the complete
loss of function of the protein. Indeed expression of the
646 C> T mutation has been shown to lead to an almost
complete loss of function [8]. It is also likely that the
splice-site mutation results in loss of function of the pro-
tein. The clinical course in patients bearing two mutations
with complete loss of function (including also stop-,
frameshift- and splice-site mutations) is significantly
worse compared to patients with at least one mutation
with residual function (partial loss of function). Signifi-
cantly more patients with two complete loss of function
mutations have ESRD and require renal replacement ther-
apy earlier in life compared to patients with residual func-
tion which may delay the progression of renal failure [8].
The observations of a rather close intra-familial concord-
ance with respect to the clinical course therefore supports
the important role of distinct CLDN16 genotypes in the
CLDN16 sequence analysis of the index case and his parents showing the heterozygous mutations Figure 2
CLDN16 sequence analysis of the index case and his parents showing the heterozygous mutations.BMC Nephrology 2008, 9:12 http://www.biomedcentral.com/1471-2369/9/12
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severity and rapidity of decline in renal function in
FHHNC [9]. Hence differences in disease severity between
families may be attributed to the location of the mutation
within the gene. Indeed, a milder clinical course which
consists of hypercalciuria during childhood with con-
served kidney function has been described in 2 families
with a homozygous mutation in the C-terminal domain
of the protein; T233R. This point mutation affects the
interaction of claudin 16 with the tight junction scaffold-
ing protein ZO-1 leading to disruption of localisation of
the protein to the tight junctions in renal epithelial cells
with accumulation in the lysosomes [16]. Other tight
junction proteins have also been implicated in FHHNC.
Recently mutations in claudin 19 (CLDN19) have been
demonstrated in several families with the classical renal
phenotype of FHHNC [17]. However the affected mem-
bers of these families also had severe visual impairment
consistent with the expression of this tight-junction pro-
tein not only in the kidney but also in the retina.
The heterozygote carriers of the family in the present
report did not exhibit any disturbances in the renal han-
dling of calcium and magnesium and did not have any
clinical evidence of nephrolithiasis as in some previously
reported families [18,19]. Thus the decision for the father
to be a kidney donor was acceptable and carried no
increased risk of stone formation for the live related
donor.
Conclusion
In conclusion the missense and splice site heterozygous
mutations in this family with classical presentation of
FHHNC affecting the second extracellular loop of
CLDN16 provides evidence of the functional importance
of the second loop in the paracellular transport of magne-
sium and calcium. In addition the severity of the clinical
presentation in the 2 affected cases points to complete
loss of function of claudin 16 and emphasises the impor-
tance of molecular diagnosis in this condition.
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